Finding better ways to predict how cancer treatments will work for patients
Statistical Methods for Identification and Evaluation of Predictive Biomarkers in Cancer
['FUNDING_R21'] · UNIVERSITY OF KENTUCKY · NIH-10866982
This study is looking for ways to improve cancer treatments by finding new markers that can help doctors figure out which patients will benefit the most from specific therapies, and if you join, your information could help shape better treatment options for everyone.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-10866982 on ClinicalTrials.gov |
What this research studies
This research focuses on improving cancer treatment outcomes by identifying new predictive biomarkers that can help determine which patients are most likely to benefit from targeted therapies. By analyzing data from non-randomized phase II clinical trials, the study aims to evaluate treatment efficacy using progression-free survival (PFS) as a key endpoint. This approach will help stratify patients into subgroups based on their likelihood of experiencing favorable or unfavorable treatment effects, ultimately guiding more effective clinical trials and drug development. Patients may have the opportunity to contribute to this important work by providing data that could lead to better treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with relapsed or refractory cancer who are undergoing treatment with targeted therapies.
Not a fit: Patients with early-stage cancer or those not receiving targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized cancer treatments, improving outcomes for patients with relapsed or refractory cancer.
How similar studies have performed: Previous research has shown promise in using predictive biomarkers to enhance treatment outcomes in cancer, indicating that this approach has potential for success.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, LI — UNIVERSITY OF KENTUCKY
- Study coordinator: CHEN, LI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology, Cancer Patient, Cancer Treatment, Cancers